Keuangan Insmed Incorporated (INSM)
NASDAQ · Healthcare · Biotechnology · Karyawan: 1.664 · CEO: William H. Lewis
- Harga
- $112,58 +0,89%
- Kapitalisasi pasar
- $24,7 M
- Nilai perusahaan
- $25 M
- Laporan terakhir
- Q3 '26 diajukan 2026-10-29
- Laporan berikutnya
- 2027-02-18 Estimasi EPS: -$0,32
Valuasi & angka utama
- Kapitalisasi pasar
- $24,7 M EV $25 M
- Pendapatan
- $1,52 M 12 bulan terakhir
- Pertumbuhan pendapatan
- +205% Konsensus FY2026
- Margin laba
- -39,9% Laba bersih / pendapatan, TTM
- P/E
- -39,9× Forward -68,0× (FY2026)
- P/S
- 16,3× Harga / penjualan, TTM
- EV / EBITDA
- -50,7× TTM
- Arus kas bebas
- -$658 jt 12 bulan terakhir
- Laba bersih
- -$606 jt 12 bulan terakhir
- Estimasi pendapatan
- $1,85 M Konsensus FY2026
- Laba
- 2027-02-18 Estimasi pendapatan: $597 jt
- Dividen
- – Tanpa dividen
Poin-poin utama
Dihitung dari angka yang dilaporkan - setiap pernyataan menyertakan angka yang mendasarinya.
- Laporan terakhir (2026-10-29): pendapatan melampaui 4,8%, EPS meleset 20,2%Pendapatan $524 jt vs $500 jt yang diharapkan (+4,8%); EPS -$0,46 vs -$0,38 (-20,2%).
- Pertumbuhan pendapatan menguat: 268,4% yoyPendapatan Q3 '26: $524 jt, rata-rata empat kuartal sebelumnya: 182,7%.
- Margin operasional -35,6% (TTM), dibanding tahun lalu: +223,3 poinLaba operasional tumbuh 53,3%, pendapatan tumbuh 240,0%.
- Capex: 4,1% dari pendapatan (tahun lalu 5,1%)$62 jt diinvestasikan dalam 4 kuartal terakhir (+172,4% dibanding tahun sebelumnya). Arus kas bebas: -$658 jt.
- Jumlah saham dilusian naik dalam setahun: 3,5%Saham dilusian pada Q3 '26: 219 jt, setahun sebelumnya: 211 jt.
- Kas neto: $405 jtKas + investasi jangka pendek: $1,15 M, utang termasuk sewa: $741 jt; tahun lalu kas neto: $935 jt.
Kuartal terakhir: Q3 '26
Kuartal berakhir 2026-09-30. Dibandingkan dengan kuartal yang sama tahun lalu dan konsensus analis sebelum laporan.
Kuartal vs tahun lalu
| Q3 '26 | Tahun lalu | Perubahan | |
|---|---|---|---|
| Pendapatan | $524 jt | $142 jt | +268,4% |
| Margin kotor | 85,1% | 79,4% | +5,7 poin |
| Laba operasional | -$89,4 jt | -$366 jt | +75,6% |
| Margin operasional | -17,0% | -257,1% | +240,1 poin |
| Laba bersih | -$100 jt | -$370 jt | +72,9% |
| EPS dilusian | -$0,46 | -$1,75 | +73,7% |
| Arus kas operasional | -$36,5 jt | -$220 jt | +83,4% |
| Capex | $5,63 jt | $2,42 jt | +132,6% |
| Arus kas bebas | -$42,1 jt | -$222 jt | +81,1% |
| R&D | $270 jt | $186 jt | +44,8% |
| Kompensasi berbasis saham | $41,2 jt | $31,4 jt | +31,1% |
Dilaporkan vs konsensus
2026-10-29| Aktual | Konsensus | vs konsensus | |
|---|---|---|---|
| Pendapatan | $524 jt | $500 jt | +4,8% |
| EPS (basis konsensus) | -$0,46 | -$0,38 | -20,2% |
Dari laporan 2026-10-29 untuk Q3 '26: pendapatan dan EPS yang diperkirakan analis (sering disesuaikan), sehingga bisa berbeda dari EPS laporan keuangan di atas.
EPS vs konsensus
8 laporan terakhirPendapatan
Dari mana uang berasal - menurut lini bisnis dan wilayah, kuartal demi kuartal.
Pendapatan, laba operasional, dan pertumbuhan
kuartalanPendapatan per lini bisnis
bertumpuk, kuartalan| Segmen | Q4 '25 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| Reportable Segment | $406 jt | – | 100,0% | – | – |
Pendapatan per wilayah
porsi dari total| Segmen | Q4 '25 | yoy | Porsi | TTM | TTM yoy | 12 kuartal |
|---|---|---|---|---|---|---|
| United States | $474 jt | +364,1% | 90,3% | $1,34 M | +265,6% | |
| Non-US | $50,8 jt | +26,1% | 9,7% | $247 jt | – |
Margin & struktur biaya
Berapa bagian dari setiap unit pendapatan yang tersisa di tiap tingkat - dan ke mana biaya mengalir.
Margin
kuartalanBiaya sebagai % pendapatan
kuartalanArus kas & alokasi modal
Kas yang dihasilkan, untuk apa kas itu digunakan, dan apa yang sampai ke pemegang saham.
Arus kas operasional, capex, arus kas bebas
kuartalanPenggunaan kas vs arus kas operasional
tahun fiskal4 kuartal terakhir
laporan arus kas- Arus kas operasional
- -$596 jt
- Capex
- -$62 jt
- Buyback
- $0
- Dividen
- $0
- Akuisisi
- -$15 jt
- Utang neto diterbitkan
- -$3,25 jt
- Kompensasi berbasis saham
- $128 jt
- Arus kas bebas
- -$658 jt
- Dikembalikan ke pemegang saham / FCF
- 0,0%
Jumlah saham dan EPS
kuartalan, dilusianNeraca
Likuiditas, investasi, dan utang pada akhir setiap kuartal.
Kas, investasi, dan utang
akhir kuartalValuasi & imbal hasil
Multiple saat ini dibandingkan lima tahun fiskal terakhir perusahaan itu sendiri; target dan peringkat analis.
Multiple dan imbal hasil
TTM vs 5 tahun fiskal| Sekarang | Rata-rata 5 th | Posisi saat ini dalam rentang 5 tahun | |
|---|---|---|---|
| P/E (TTM) | -39,9× | – | – |
| EV / EBITDA | -50,7× | – | – |
| EV / Penjualan | 16,5× | 27,5× | 10,4× – 61,7× |
| Harga / FCF | -37,6× | – | – |
| Harga / Nilai buku | 33,9× | 31,3× 4 dari 5 tahun | 7,4× – 50,3× |
| Imbal hasil FCF | -2,7% | -10,1% | -16,7% – -2,6% |
| Imbal hasil modal yang diinvestasikan | -32,8% | -48,7% | -64,8% – -31,0% |
| Imbal hasil ekuitas | -82,7% | -184,1% | -547,5% – 225,8% |
Analis
Target konsensus $191,31 (+69,9%)
rentang $154,00 – $235,00 · peringkat Buy
Prospek
Konsensus analis untuk tahun fiskal mendatang dan implikasinya pada harga saat ini.
Estimasi konsensus
| Tahun fiskal | Pendapatan | Pertumbuhan | EPS | Pertumbuhan | P/E pada harga saat ini | Analis (EPS) |
|---|---|---|---|---|---|---|
| FY2026 | $1,85 M | +204,5% | -$1,65 | +74,2% | -68,0× | 14 |
| FY2027 | $2,97 M | +61,0% | $0,65 | +139,4% | 172,6× | 14 |
| FY2028 | $3,96 M | +33,0% | $3,16 | +384,8% | 35,6× | 16 |
| FY2029 | $4,99 M | +26,0% | $6,37 | +101,4% | 17,7× | 13 |
| FY2030 | $6,21 M | +24,6% | $9,98 | +56,8% | 11,3× | 13 |
Laporan keuangan
Setiap baris laporan laba rugi, neraca, dan laporan arus kas - 12 kuartal dan 10 tahun fiskal, sebagai nilai, % pendapatan, atau pertumbuhan.
Semua pos yang dilaporkan
Semua 240 angka yang ditandai Insmed Incorporated dalam laporan 10-Q / 10-K terbarunya, dengan label dan definisi resmi SEC - termasuk catatan (sewa, pajak, buyback, karyawan, ...).
| Pos (label SEC) | Kuartal terakhir | Tahun lalu | yoy | FY terakhir | FY sebelumnya | yoy |
|---|---|---|---|---|---|---|
| Accounts Payable and Accrued Liabilities, Current | $575 jt | $410 jt | +40,2% | $456 jt | $285 jt | +59,9% |
| Accounts Payable, Current | $84,3 jt | $79,6 jt | +5,9% | $79,9 jt | $73 jt | +9,4% |
| Accounts Receivable, after Allowance for Credit Loss, Current | $259 jt | $65,3 jt | +297,3% | $141 jt | $52 jt | +170,8% |
| Accrued Professional Fees | $34,3 jt | $25,8 jt | +33,0% | $23,7 jt | $17,9 jt | +32,2% |
| Accrued Royalties | $146 jt | $164 jt | -10,8% | $163 jt | $161 jt | +1,1% |
| Accrued Royalties, Current | $10,2 jt | $9,37 jt | +9,2% | $17,1 jt | $6,32 jt | +170,4% |
| Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | $70,1 jt | $57,2 jt | +22,5% | $60,8 jt | $50,3 jt | +20,8% |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | -$40 rb | $2 jt | -102,0% | $1,46 jt | -$2,29 jt | +163,8% |
| Additional Paid in Capital | $6,64 M | $6,25 M | +6,2% | $6,37 M | $4,65 M | +37,2% |
| Amortization of Debt Issuance Costs | $1,48 jt | $1,34 jt | +10,3% | $6,22 jt | $6,88 jt | -9,7% |
| Amortization of Debt Issuance Costs and Discounts | $1,48 jt | $1,34 jt | +10,3% | $6,22 jt | $6,88 jt | -9,7% |
| Amortization of Intangible Assets | $5,05 jt | $1,54 jt | +228,3% | $6 jt | $5,05 jt | +18,8% |
| APIC, Share-based Payment Arrangement, Increase for Cost Recognition | $41,2 jt | $31,4 jt | +31,1% | $153 jt | $96,8 jt | +57,7% |
| Assets | $2,23 M | $2,36 M | -5,7% | $2,26 M | $2,03 M | +11,8% |
| Assets, Current | $1,71 M | $1,93 M | -11,7% | $1,79 M | $1,62 M | +10,6% |
| Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability | $7,54 jt | $105 jt | -92,8% | $252 jt | $91,7 jt | +174,9% |
| Business Combination, Contingent Consideration, Liability, Current | $0 | $42,5 jt | -100,0% | $57,8 jt | $24,7 jt | +134,0% |
| Business Combination, Contingent Consideration, Liability, Noncurrent | $178 jt | $260 jt | -31,4% | $314 jt | $144 jt | +118,0% |
| Cash and Cash Equivalents, at Carrying Value | $397 jt | $335 jt | +18,5% | $510 jt | $555 jt | -8,0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $397 jt | $335 jt | +18,5% | $510 jt | $555 jt | -8,0% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | -$148 jt | -$950 jt | +84,4% | -$44,6 jt | $72,7 jt | -161,4% |
| Common Stock, Par or Stated Value Per Share | $0,01 | $0,01 | 0,0% | $0,01 | $0,01 | 0,0% |
| Common Stock, Shares Authorized | 500 jt | 500 jt | 0,0% | 500 jt | 500 jt | 0,0% |
| Common Stock, Shares, Issued | 219 jt | 213 jt | +3,2% | 214 jt | 179 jt | +19,4% |
| Common Stock, Shares, Outstanding | 219 jt | 213 jt | +3,2% | 214 jt | 179 jt | +19,4% |
| Common Stock, Value, Issued | $2,19 jt | $2,13 jt | +3,2% | $2,14 jt | $1,79 jt | +19,5% |
| Comprehensive Income (Loss), Net of Tax, Attributable to Parent | -$97 jt | -$370 jt | +73,8% | -$1,27 M | -$915 jt | -39,1% |
| Contract with Customer, Asset, Allowance for Credit Loss | $79,4 jt2025-12-31 | $22,3 jt | +256,5% | $79,4 jt | $22,3 jt | +256,5% |
| Contract with Customer, Refund Liability, Current | $4,19 jt | $10 jt | -58,3% | $6,96 jt | $5,99 jt | +16,2% |
| Cost of Goods and Services Sold | $78,2 jt | $29,4 jt | +166,4% | $123 jt | $85,7 jt | +43,4% |
| Costs and Expenses | $614 jt | $508 jt | +20,7% | $1,85 M | $1,24 M | +49,2% |
| Current Federal Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Current Foreign Tax Expense (Benefit) | – | – | – | $4,48 jt | $3,38 jt | +32,4% |
| Current Income Tax Expense (Benefit) | – | – | – | $5,05 jt | $3,74 jt | +35,3% |
| Current State and Local Tax Expense (Benefit) | – | – | – | $577 rb | $356 rb | +62,1% |
| Debt Securities, Available-for-sale | $750 jt | $1,35 M | -44,2% | $920 jt | $879 jt | +4,6% |
| Debt Securities, Available-for-sale, Unrealized Gain | – | – | – | $400 rb | $300 rb | +33,3% |
| Deferred Federal Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Foreign Income Tax Expense (Benefit) | – | – | – | $0 | $0 | – |
| Deferred Income Tax Expense (Benefit) | $0 | $0 | – | -$27 rb | -$29 rb | +6,9% |
| Deferred State and Local Income Tax Expense (Benefit) | – | – | – | -$27 rb | -$29 rb | +6,9% |
| Deferred Tax Assets, Gross | $1,46 M2025-12-31 | $1,14 M | +28,6% | $1,46 M | $1,14 M | +28,6% |
| Deferred Tax Assets, in Process Research and Development | $167 jt2025-12-31 | $178 jt | -5,9% | $167 jt | $178 jt | -5,9% |
| Deferred Tax Assets, Net of Valuation Allowance | $7,1 jt2025-12-31 | $12,5 jt | -43,1% | $7,1 jt | $12,5 jt | -43,1% |
| Deferred Tax Assets, Operating Loss Carryforwards | $956 jt2025-12-31 | $673 jt | +42,1% | $956 jt | $673 jt | +42,1% |
| Deferred Tax Assets, Other | $41,6 jt2025-12-31 | $38,5 jt | +8,1% | $41,6 jt | $38,5 jt | +8,1% |
| Deferred Tax Assets, Tax Credit Carryforwards, General Business | $268 jt2025-12-31 | $218 jt | +22,9% | $268 jt | $218 jt | +22,9% |
| Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | $30,9 jt2025-12-31 | $30,7 jt | +0,5% | $30,9 jt | $30,7 jt | +0,5% |
| Deferred Tax Assets, Valuation Allowance | $1,46 M2025-12-31 | $1,13 M | +29,4% | $1,46 M | $1,13 M | +29,4% |
| Deferred Tax Liabilities, Gross | $7,13 jt2025-12-31 | $12,5 jt | -43,1% | $7,13 jt | $12,5 jt | -43,1% |
| Deferred Tax Liabilities, Intangible Assets | $02025-12-31 | $5,58 jt | -100,0% | $0 | $5,58 jt | -100,0% |
| Deferred Tax Liabilities, Leasing Arrangements | $7,13 jt2025-12-31 | $6,95 jt | +2,5% | $7,13 jt | $6,95 jt | +2,5% |
| Deferred Tax Liabilities, Net | $29 rb2025-12-31 | $55 rb | -47,3% | $29 rb | $55 rb | -47,3% |
| Defined Contribution Plan, Employer Discretionary Contribution Amount | – | – | – | $12,8 jt | $7,4 jt | +73,0% |
| Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay | – | – | – | 5,0% | 4,0% | +25,0% |
| Defined Contribution Plan, Employer Matching Contribution, Percent of Match | – | – | – | 100,0% | 100,0% | 0,0% |
| Depreciation | $3,35 jt | $2,46 jt | +36,1% | $10,4 jt | $5,96 jt | +75,3% |
| Earnings Per Share, Basic | -$0,46 | -$1,75 | +73,7% | -$6,42 | -$5,57 | -15,3% |
| Earnings Per Share, Diluted | -$0,46 | -$1,75 | +73,7% | -$6,42 | -$5,57 | -15,3% |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | $269 rb | -$976 rb | +127,6% | $931 rb | -$1,31 jt | +171,2% |
Sumber: SEC companyfacts (XBRL setiap 10-Q / 10-K). Kuartal arus kas dihitung dari angka kumulatif tahun berjalan yang ditandai dalam 10-Q. Rincian segmen ditandai dengan dimensi dan ditampilkan di bagian segmen.
Sumber
Laporan keuangan, pendapatan segmen, metrik, dan estimasi distandardisasi dari laporan perusahaan. Laba segmen dan setiap pos yang dilaporkan: SEC EDGAR (XBRL). Laporan yang dibaca: 10-Q 2026-09-30, 10-Q 2026-06-30, 10-Q 2026-03-31, 10-K 2025-12-31, 10-Q 2025-09-30, 10-Q 2025-06-30, 10-Q 2025-03-31, 10-K 2024-12-31, 10-Q 2024-09-30
Data per 2026-11-02